{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T20:39:26Z","timestamp":1775075966170,"version":"3.50.1"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001475","name":"Nanyang Technological University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001475","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Colloids and Surfaces B: Biointerfaces"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.colsurfb.2020.111095","type":"journal-article","created":{"date-parts":[[2020,5,11]],"date-time":"2020-05-11T09:54:44Z","timestamp":1589190884000},"page":"111095","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Ternary nanoparticle complex of antibiotic, polyelectrolyte, and mucolytic enzyme as a potential antibiotic delivery system in bronchiectasis therapy"],"prefix":"10.1016","volume":"193","author":[{"given":"The-Thien","family":"Tran","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kunn","family":"Hadinoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.colsurfb.2020.111095_bib0005","first-page":"715","article-title":"Bronchiectasis: new therapies and new perspectives, Lancet Respir","volume":"6","author":"Chalmers","year":"2018","journal-title":"Med."},{"key":"10.1016\/j.colsurfb.2020.111095_bib0010","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1183\/09031936.00018414","article-title":"Inhaled antibiotics for stable non-cystic fibrosis bronchiectasis: a systematic review","volume":"44","author":"Brodt","year":"2014","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.colsurfb.2020.111095_bib0015","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1183\/09031936.00119114","article-title":"Management of bronchiectasis in adults","volume":"45","author":"Chalmers","year":"2015","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.colsurfb.2020.111095_bib0020","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jconrel.2014.11.022","article-title":"Antimicrobial efficacy of tobramycin polymeric nanoparticles for Pseudomonas aeruginosa infections in cystic fibrosis: formulation, characterisation and functionalisation with dornase alfa (DNase)","volume":"198","author":"Deacon","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.colsurfb.2020.111095_bib0025","doi-asserted-by":"crossref","DOI":"10.3390\/microorganisms5030035","article-title":"Free and nanoencapsulated tobramycin: effects on planktonic and biofilm forms of Pseudomonas","volume":"5","author":"Sans-Serramitjana","year":"2017","journal-title":"Microorganisms"},{"key":"10.1016\/j.colsurfb.2020.111095_bib0030","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jcf.2013.07.004","article-title":"Investigating the role of matrix components in protection of Burkholderia cepacia complex biofilms against tobramycin","volume":"13","author":"Messiaen","year":"2014","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.colsurfb.2020.111095_bib0035","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.jcf.2015.12.005","article-title":"Killing effect of nanoencapsulated colistin sulfate on Pseudomonas aeruginosa from cystic fibrosis patients","volume":"15","author":"Sans-Serramitjana","year":"2016","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.colsurfb.2020.111095_bib0040","first-page":"1906","article-title":"Tailored nanocarriers for the pulmonary delivery of levofloxacin against Pseudomonas aeruginosa: a comparative study","volume":"16","author":"Derbali","year":"2019","journal-title":"J. Mol. Pharm. Org. Process Res."},{"key":"10.1016\/j.colsurfb.2020.111095_bib0045","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.ejpb.2017.04.032","article-title":"Ciprofloxacin-loaded PLGA nanoparticles against cystic fibrosis P-aeruginosa lung infections","volume":"117","author":"Tureli","year":"2017","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.colsurfb.2020.111095_bib0050","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.ijpharm.2016.10.025","article-title":"Optimization of ciprofloxacin complex loaded PLGA nanoparticles for pulmonary treatment of cystic fibrosis infections: design of experiments approach","volume":"515","author":"Tureli","year":"2016","journal-title":"Int J. Pharmaceut."},{"key":"10.1016\/j.colsurfb.2020.111095_bib0055","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics8010006","article-title":"Development of liposomal ciprofloxacin to treat lung infections","volume":"8","author":"Cipolla","year":"2016","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.colsurfb.2020.111095_bib0060","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.ijpharm.2018.06.017","article-title":"A new therapeutic avenue for bronchiectasis: dry powder inhaler of ciprofloxacin nanoplex exhibits superior ex vivo mucus permeability and antibacterial efficacy to its native ciprofloxacin counterpart","volume":"547","author":"Tran","year":"2018","journal-title":"Int. J. Pharmaceut."},{"key":"10.1016\/j.colsurfb.2020.111095_bib0065","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ijpharm.2017.05.013","article-title":"Ciprofloxacin-loaded lipid-core nanocapsules as mucus penetrating drug delivery system intended for the treatment of bacterial infections in cystic fibrosis","volume":"527","author":"Torge","year":"2017","journal-title":"Int. J. Pharmaceut."},{"key":"10.1016\/j.colsurfb.2020.111095_bib0070","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.ijpharm.2018.06.005","article-title":"Development of self-emulsifying drug delivery systems (SEDDS) for ciprofloxacin with improved mucus permeating properties","volume":"547","author":"Zaichik","year":"2018","journal-title":"Int. J. Pharmaceut."},{"key":"10.1016\/j.colsurfb.2020.111095_bib0075","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.colsurfb.2014.02.032","article-title":"Nano-antibiotics in chronic lung infection therapy against Pseudomonas aeruginosa","volume":"116","author":"Hadinoto","year":"2014","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.colsurfb.2020.111095_bib0080","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.1128\/AAC.49.8.3222-3227.2005","article-title":"Ciprofloxacin induction of a susceptibility determinant in Pseudomonas aeruginosa","volume":"49","author":"Brazas","year":"2005","journal-title":"Antimicrob. Agents Ch."},{"key":"10.1016\/j.colsurfb.2020.111095_bib0085","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.rmed.2016.06.007","article-title":"Challenges in managing Pseudomonas aeruginosa in non-cystic fibrosis bronchiectasis","volume":"117","author":"Wilson","year":"2016","journal-title":"Respir. Med."},{"key":"10.1016\/j.colsurfb.2020.111095_bib0090","article-title":"Inhaled anti-pseudomonal antibiotics for long-term therapy in cystic fibrosis","author":"Smiths","year":"2018","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.colsurfb.2020.111095_bib0095","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S2213-2600(18)30427-2","article-title":"Inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchiectasis and chronic lung infection with Pseudomonas aeruginosa (ORBIT-3 and ORBIT-4): two phase 3, randomised controlled trials","volume":"7","author":"Haworth","year":"2019","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.colsurfb.2020.111095_bib0100","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.jcis.2011.10.011","article-title":"Self-assembled amorphous drug-polyelectrolyte nanoparticle complex with enhanced dissolution rate and saturation solubility","volume":"367","author":"Cheow","year":"2012","journal-title":"J. Colloid Interface Sci."},{"key":"10.1016\/j.colsurfb.2020.111095_bib0105","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.ijpharm.2019.01.062","article-title":"An evaluation of inhaled antibiotic liposome versus antibiotic nanoplex in controlling infection in bronchiectasis","volume":"559","author":"Tran","year":"2019","journal-title":"Int. J. Pharmaceut."},{"key":"10.1016\/j.colsurfb.2020.111095_bib0110","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1136\/thoraxjnl-2014-205587","article-title":"Inhaled mannitol for non-cystic fibrosis bronchiectasis: a randomised, controlled trial","volume":"69","author":"Bilton","year":"2014","journal-title":"Thorax"},{"key":"10.1016\/j.colsurfb.2020.111095_bib0115","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ejpb.2015.01.008","article-title":"Nanoparticles decorated with proteolytic enzymes, a promising strategy to overcome the mucus barrier","volume":"97","author":"de Sousa","year":"2015","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.colsurfb.2020.111095_bib0120","doi-asserted-by":"crossref","DOI":"10.1007\/s11051-012-1353-z","article-title":"Preparation and characterization of mucus-penetrating papain\/poly(acrylic acid) nanoparticles for oral drug delivery applications","volume":"15","author":"Muller","year":"2013","journal-title":"J. Nanopart. Res."},{"key":"10.1016\/j.colsurfb.2020.111095_bib0125","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.ijpharm.2017.08.059","article-title":"Development and in vitro characterization of a papain loaded mucolytic self-emulsifying drug delivery system (SEDDS)","volume":"530","author":"Leichner","year":"2017","journal-title":"Int. J. Pharmaceut."},{"key":"10.1016\/j.colsurfb.2020.111095_bib0130","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ejpb.2013.12.012","article-title":"Development and in vivo evaluation of papain-functionalized nanoparticles","volume":"87","author":"Muller","year":"2014","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.colsurfb.2020.111095_bib0135","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.addr.2017.10.004","article-title":"Enzyme decorated drug carriers: targeted swords to cleave and overcome the mucus barrier","volume":"124","author":"Menzel","year":"2018","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.colsurfb.2020.111095_bib0140","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1007\/s11095-006-9226-8","article-title":"Papain: an effective permeation enhancer for orally administered low molecular weight heparin","volume":"24","author":"Grabovac","year":"2007","journal-title":"Pharm. Res."},{"key":"10.1016\/j.colsurfb.2020.111095_bib0145","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1080\/10601329409349716","article-title":"Complexation of papain with strong polyanions and enzymatic-activities of the resulting complexes","volume":"A31","author":"Izumi","year":"1994","journal-title":"J. Macromol. Sci.-Pure Appl. Chem."},{"key":"10.1016\/j.colsurfb.2020.111095_bib0150","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1107\/S2052520615018582","article-title":"Salt screening and characterization of ciprofloxacin","volume":"72","author":"Zhang","year":"2016","journal-title":"Acta Crystallogr. B-Struct. Sci. Cryst. Eng. Mater."},{"key":"10.1016\/j.colsurfb.2020.111095_bib0155","first-page":"2280","article-title":"Disruption of the mucus barrier by topically applied exogenous particles","volume":"7","author":"McGill","year":"2010","journal-title":"J. Mol. Pharm. Org. Process Res."},{"key":"10.1016\/j.colsurfb.2020.111095_bib0160","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1016\/j.biomaterials.2008.12.076","article-title":"The penetration of fresh undiluted sputum expectorated by cystic fibrosis patients by non-adhesive polymer nanoparticles","volume":"30","author":"Suk","year":"2009","journal-title":"Biomaterials"},{"key":"10.1016\/j.colsurfb.2020.111095_bib0165","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0378-5173(97)04913-2","article-title":"Crystal structure of ciprofloxacin hexahydrate and its characterization","volume":"152","author":"Turel","year":"1997","journal-title":"Int J Pharmaceut"},{"key":"10.1016\/j.colsurfb.2020.111095_bib0170","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.ejpb.2017.09.009","article-title":"Preparation and characterization of amorphous ciprofloxacin-amino acid salts","volume":"121","author":"Mesallati","year":"2017","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.colsurfb.2020.111095_bib0175","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.apsusc.2015.03.004","article-title":"Transport and antifouling properties of papain-based antifouling coatings","volume":"341","author":"Peres","year":"2015","journal-title":"Appl. Surf. Sci."},{"key":"10.1016\/j.colsurfb.2020.111095_bib0180","doi-asserted-by":"crossref","first-page":"313","DOI":"10.3109\/03639049809085626","article-title":"Extension of the international conference on harmonization tripartite guideline for stability testing of new drug substances and products to countries of climatic zones III and IV, drug dev","volume":"24","author":"Grimm","year":"1998","journal-title":"Ind. Pharm."},{"key":"10.1016\/j.colsurfb.2020.111095_bib0185","doi-asserted-by":"crossref","first-page":"923","DOI":"10.3390\/biom3040923","article-title":"Research applications of proteolytic enzymes in molecular biology","volume":"3","author":"Motyan","year":"2013","journal-title":"Biomolecules"}],"container-title":["Colloids and Surfaces B: Biointerfaces"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0927776520303258?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0927776520303258?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T10:51:54Z","timestamp":1760525514000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0927776520303258"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":37,"alternative-id":["S0927776520303258"],"URL":"https:\/\/doi.org\/10.1016\/j.colsurfb.2020.111095","relation":{},"ISSN":["0927-7765"],"issn-type":[{"value":"0927-7765","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ternary nanoparticle complex of antibiotic, polyelectrolyte, and mucolytic enzyme as a potential antibiotic delivery system in bronchiectasis therapy","name":"articletitle","label":"Article Title"},{"value":"Colloids and Surfaces B: Biointerfaces","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.colsurfb.2020.111095","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"111095"}}